Mass balance study of [(1)(4)C]eribulin in patients with advanced solid tumors.

A.C. Dubbelman; H. Rosing; R.S. Jansen; M. Mergui-Roelvink; AD Huitema; B. Koetz; M. Lymboura; L. Reyderman; A. Lopez-Anaya; J.H.M. Schellens; J.H. Beijnen

Mass balance study of [(1)(4)C]eribulin in patients with advanced solid tumors.

A.C. Dubbelman, H. Rosing, R.S. Jansen, M. Mergui-Roelvink, AD Huitema, B. Koetz, M. Lymboura, L. Reyderman, A. Lopez-Anaya, J.H.M. Schellens, J.H. Beijnen

extern

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

This mass balance study investigated the metabolism and excretion of eribulin, a nontaxane microtubule dynamics inhibitor with a novel mechanism of action, in patients with advanced solid tumors. A single approximately 2 mg (approximately 80 muCi) dose of [(1)(4)C]eribulin acetate was administered as a 2 to 5 min bolus injection to six patients on day 1. Blood, urine, and fecal samples were collected at specified time points on days 1 to 8 or until sample radioactivity was

Original language	Undefined/Unknown
Pages (from-to)	313-21
Number of pages	9
Journal	Drug Metabolism and Disposition
Volume	40
Issue number	2
Publication status	Published - 2012

Cite this

@article{f59f9967b097400a95648906eb6a7b26,

title = "Mass balance study of [(1)(4)C]eribulin in patients with advanced solid tumors.",

abstract = "This mass balance study investigated the metabolism and excretion of eribulin, a nontaxane microtubule dynamics inhibitor with a novel mechanism of action, in patients with advanced solid tumors. A single approximately 2 mg (approximately 80 muCi) dose of [(1)(4)C]eribulin acetate was administered as a 2 to 5 min bolus injection to six patients on day 1. Blood, urine, and fecal samples were collected at specified time points on days 1 to 8 or until sample radioactivity was",

author = "A.C. Dubbelman and H. Rosing and R.S. Jansen and M. Mergui-Roelvink and AD Huitema and B. Koetz and M. Lymboura and L. Reyderman and A. Lopez-Anaya and J.H.M. Schellens and J.H. Beijnen",

year = "2012",

language = "Undefined/Unknown",

volume = "40",

pages = "313--21",

journal = "Drug Metabolism and Disposition",

issn = "0090-9556",

publisher = "Elsevier Inc.",

number = "2",

}

TY - JOUR

T1 - Mass balance study of [(1)(4)C]eribulin in patients with advanced solid tumors.

AU - Dubbelman, A.C.

AU - Rosing, H.

AU - Jansen, R.S.

AU - Mergui-Roelvink, M.

AU - Huitema, AD

AU - Koetz, B.

AU - Lymboura, M.

AU - Reyderman, L.

AU - Lopez-Anaya, A.

AU - Schellens, J.H.M.

AU - Beijnen, J.H.

PY - 2012

Y1 - 2012

N2 - This mass balance study investigated the metabolism and excretion of eribulin, a nontaxane microtubule dynamics inhibitor with a novel mechanism of action, in patients with advanced solid tumors. A single approximately 2 mg (approximately 80 muCi) dose of [(1)(4)C]eribulin acetate was administered as a 2 to 5 min bolus injection to six patients on day 1. Blood, urine, and fecal samples were collected at specified time points on days 1 to 8 or until sample radioactivity was

AB - This mass balance study investigated the metabolism and excretion of eribulin, a nontaxane microtubule dynamics inhibitor with a novel mechanism of action, in patients with advanced solid tumors. A single approximately 2 mg (approximately 80 muCi) dose of [(1)(4)C]eribulin acetate was administered as a 2 to 5 min bolus injection to six patients on day 1. Blood, urine, and fecal samples were collected at specified time points on days 1 to 8 or until sample radioactivity was

M3 - Article

SN - 0090-9556

VL - 40

SP - 313

EP - 321

JO - Drug Metabolism and Disposition

JF - Drug Metabolism and Disposition

IS - 2

ER -